AI health-tech company Stellarcube announced on the 18th that it has signed a strategic business agreement with GenBODY for technology and business exchange.

The agreement aims to share the companies’ expertise and business experience in diagnostic technology, biotechnology, and medical AI solutions, and to combine these capabilities to create new business opportunities based on AI–bio convergence. Both companies expect the partnership to simultaneously strengthen their technological competitiveness and expand their businesses.

Stellarcube recently entered into a joint research agreement with Korea University Anam Hospital and Johns Hopkins to accelerate the development of “PainX,” a next-generation pain management solution.

PainX is an AI-based solution that automates pain prediction, diagnosis, and medication recommendation based on multiple biosignals such as ECG and PPG. It is designed to address key limitations of conventional pain management, including subjective assessment, reliance on medical staff experience, and inconsistencies in analgesic administration.

By predicting a patient’s pain in advance and supporting clinical decision-making, it is regarded as an innovative technology that can drive a paradigm shift in conventional pain management methods.

Stellarcube is also expanding its AI healthcare business portfolio with the launch of its health management platform HelciO. HelciO is an AI healthcare platform in which five domains—AX Lab, Health Management, Life, Well, and Data Hub—are organically connected. It provides AI-based health management technologies not only for senior care but also for chronic disease management and for pregnant women struggling with infertility.

GenBODY is an in vitro diagnostics specialist that has proven its technological capabilities and reliability in the global market with its COVID-19 diagnostic kits. The company holds international certifications including CE IVDR, WHO PQ, and FDA approvals, and since the endemic phase has been targeting overseas markets with a broad range of diagnostic kit products for AIDS, syphilis, and drugs of abuse, as well as self-testing platforms.

Under the MOU, the two companies plan to pursue in stages: ▲ technology and business exchange ▲ exploration of joint research and development opportunities combining diagnostic and biotechnology with AI solutions ▲ collaboration to expand into domestic and overseas markets ▲ review of long-term strategic cooperation plans.

Stellarcube CEO Noh Jin-seop said, “Through this MOU, Stellarcube and GenBODY plan to significantly expand their AI-based healthcare solution business by organically combining their respective technologies, know-how, and networks,” adding, “It is meaningful that, through the HelciO platform, we can work with GenBODY to further advance technologies that precisely collect and analyze the physiological characteristics and hormonal changes of infertility patients, and that utilize AI-based prediction models to detect early key risk signals such as ovulation and implantation timing and ovarian hyperstimulation syndrome (OHSS).”

Popular News